News Feed

By Carolyn Crist

(Reuters Health) - Patients commonly hold back information from doctors that could help in their healthcare, which could influence the care they receive or even harm them, researchers say.

By Reuters Staff

ZURICH (Reuters) - Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria.

Xolair is sold by both Novartis and Roche, but has lost patent protection in Europe and the United States, leaving it exposed to rivals who are developing copies of the biological drug. None are yet on the market.

By Reuters Staff

(Reuters) - Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

The successful completion of the trial paves the way for Revance to submit its application for marketing approval of the drug in the first half of 2019, the company said.

By Marilynn Larkin

NEW YORK (Reuters Health) - Dapsone is an effective second-line treatment for chronic spontaneous urticaria (CSU) patients in whom antihistamines and other first-line therapies have failed, researchers say.

By Lisa Rapaport

(Reuters Health) - Although telemedicine visits have increased sharply in the U.S. in recent years, the vast majority of American adults still receive care from doctors in person rather than via remote technology, a new study suggests.

By Reuters Staff

NEW YORK (Reuters Health) - Treatment with lanadelumab significantly reduced attacks of hereditary angioedema (HAE) type I and II in the phase 3 randomized controlled HELP study, supporting its use as a prophylactic therapy for HAE, researchers say.

By Marilynn Larkin

NEW YORK (Reuters Health) - Home treatment with tazarotene gel was as effective as microneedling in improving acne scar severity, in a small trial in India.

By Rob Goodier

NEW YORK (Reuters Health) - Subcutaneous allergen immunotherapy appears to have reduced a patient’s symptoms of severe eczema, according to a new case study.

By Marilynn Larkin

NEW YORK (Reuters Health) - Compared with placebo, a single injection of platelet-rich plasma (PRP) may reduce signs of photoaging as perceived by recipients of the treatment, researchers say.

By Will Boggs MD

NEW YORK (Reuters Health) - Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD).